

## Tanja Mueller (she/her)

Work address                      Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS)  
University of Strathclyde  
161 Cathedral Street, Glasgow, G4 0RE

ORCID ID                              0000-0002-0418-4789

---

### Current role

Since April 2022, I have been working as a Lecturer in Pharmacoepidemiology and Health Services Research at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). My academic time is split between various research projects and a range of teaching activities within the department; I also supervise both undergraduate and postgraduate students.

### Research

My research interests fall under two broad areas: pharmacoepidemiology; and health services research. In the area of pharmacoepidemiology, my main interest is drug utilisation (including, but not limited to, uptake of medication and adherence to treatment). In the area of health services research, my focus is on data driven approaches to improve clinical care in its widest sense – from the impact of policies, legislation, and regulation on access to health care; to the effect of social and/or environmental factors on health.

### Employment history (selection)

Oct 2017 – Mar 2022    **Research Assistant/Research Associate**  
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow

Feb 2003 – Oct 2011    **Community pharmacist**  
Various posts (including assistant store manager/store manager); Germany

### Education (selection)

June 2021                **Fellow** of the Higher Education Academy (UK)

2014 – 2017            **PhD (Pharmacoepidemiology)** – University of Strathclyde, Glasgow  
Farr Institute of Health Informatics Research PhD studentship

2012 – 2014            **Master of Medical Sciences (Public Health)** – Lund University, Sweden  
2-year programme

Jan 2003                **License to practice** as a pharmacist (Germany)

1997 – 2002            **Staatsexamen (MPharm equivalent)** – Braunschweig University of Technology, Germany

### Most recent publications (selection)

- 1    Komen JJ, Hunt NB, Pottegård A, Hjemdahl P, Wettermark B, Olesen M, Bennie M, **Mueller T**, Carragher R, Karlstad Ø, Kjerpeseth LJ, Klungel OH & Forslund T (2023). Heterogeneity after harmonisation: a retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries. *Pharmacoepidemiol Drug Saf.* Online ahead of print, 1-10.

- 2 Mahmoud F, Mullen A, Sainsbury C, Rushworth GF, Yasin H, Abutheraa N, **Mueller T** & Kurdi A (2023). Meta-analysis of Factors Associated with Antidiabetic Drug Prescribing for Type 2 Diabetes Mellitus. *Eur J Clin Invest*. Online ahead of print, e13997.
- 3 Kurdi A, Platt N, Morrison A, Proud E, Gronkowski K, **Mueller T**, Seaton RA, Malcolm W & Bennie M (2023). Evaluation of duration of antibiotic therapy across hospitals in Scotland including the impact of COVID-19 pandemic: a segmented interrupted time series analysis. *Expert Review of Anti-Infective Therapy*, 21(4), 455-475.
- 4 Tibble H, **Mueller T**, Proud E, Hall E, Kurdi A, Robertson C, Bennie M, Woolford L & Sheikh A (2023). Uptake of monoclonal antibodies and antiviral therapies for COVID-19 in Scotland. *The Lancet*, 401 (10371), 101-102.
- 5 Kurdi A, **Mueller T** & Weir N (2023). An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes. *Eur J Clin Invest*, 53, e13888.
- 6 **Mueller T**, Kurdi A, Hall E, Bullard I, Wapshott J, Goodfellow A, Platt N, Proud E, McTaggart S, Bennie M & Sheikh A (2022). Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study. *BMJ Open*, 12(12), e064320.
- 7 Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, Hallas J, Olesen M, Bennie M, **Mueller T**, Carragher R, Karlstad Ø, Kjerpeseth LJ & Klungel OH (2022). Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. *European Heart Journal*, 43(37), 3528-3538.
- 8 **Mueller T**, Laskey J, Baillie K, Clarke J, Crearie C, Kavanagh K, Graham J, Graham K, Waterston A, Jones R, Kurdi A, Morrison D & Bennie M (2022). Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. *Health Informatics Journal*, 28(1).
- 9 Dunlop E, Ferguson A, **Mueller T**, Baillie K, Clarke J, Laskey J, Kurdi A, Wu O, Jones R, Glen H & Bennie M (2022). What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed-methods approach in prostate cancer. *Supportive Care in Cancer*, 30(4), 3141-3150.
- 10 **Mueller T**, Preston KE, Weir NM, Bennie M & Newham R (2021). Competencies required for General Practice Clinical Pharmacists providing the Scottish Pharmacotherapy Service: A modified eDelphi study. *Health and Social Care in the Community*, 29(6), e328-e337.